Microdialysis administration of vasopressin and vasopressin antagonists into the septum during pole-jumping behavior in rats.
Wistar rats (n = 95) were trained in a pole-jumping apparatus (10 trials/session/day) to investigate the involvement of centrally and peripherally released endogenous AVP in their acquisition rate and to examine the feasibility of the microdialysis technique for the administration of peptides during a behavioral test. After session 1, a microdialysis probe was implanted into the septum; during sessions 2 and 3 the probe was perfused with artificial cerebrospinal fluid (aCSF) alone or containing either AVP (delivered amount via the probe: 0.2 ng) or the V1 (d(CH2)5Tyr(Me)AVP, 5.0 ng) or the V2/V1 (d(CH2)5-D-Tyr(Et)VAVP, 5.0 ng) antagonist. Administration of AVP via microdialysis into the septum failed to alter the acquisition rate of pole jumping. Also, ip application of both hypertonic saline and the AVP V1 antagonist (10 micrograms) in another experiment failed to show a significant effect upon behavior. Septal administration of the V1 or the V2/V1 antagonist via microdialysis, however, produced a significantly impaired performance. The results indicate that AVP release within the septum is involved in the acquisition of pole-jumping behavior probably mediated by the V1 receptor subtype. An additional involvement of the V2 receptor subtype, however, cannot be entirely excluded. The microdialysis technique proved to be a potent tool to administer substances concomitantly with behavioral tests.
Engelmann
M
M
Section of Biosciences, University of Leipzig, Germany.
Ludwig
M
M
Landgraf
R
R
D000818:Animals; D001127:Arginine Vasopressin; D001522:Behavior, Animal / Q000187:drug effects; D007274:Injections, Intraperitoneal; D007858:Learning; D008297:Male; D010455:Peptides; D019736:Prostheses and Implants; D051381:Rats; D017208:Rats, Wistar; D012688:Septum Pellucidum / Q000187:drug effects*; D014667:Vasopressins
D010455:Peptides; D014667:Vasopressins; D001127:Arginine Vasopressin